NasdaqGS:NVCRMedical Equipment
NovoCure (NVCR): Losses Worsen, Testing Bullish Narrative on Valuation and Growth Potential
NovoCure (NVCR) remains unprofitable, with net losses increasing at an annual rate of 40.7% over the past five years and no improvement in net profit margins. For investors, the key reward comes from revenue, which is forecast to grow at 12.9% per year, well ahead of the broader US market’s expected 10.3% growth. The trading price of $12.81 sits below its estimated fair value of $60.99. Despite these positives, the company is projected to stay unprofitable for at least the next three years,...